BenevolentAI was founded in 2013 and is headquartered in London, GB
Report incorrect company information
Key People/Management at BenevolentAI
Jackie Fmedsc
Director
Kenneth Mulvany
Director
Jerome Pesenti
Non-Executive Director
Bart Swanson
Non-Executive Director
Joanna Shields
Group CEO
Amir Saffari
SVP Artificial Intelligence
Report incorrect company information
BenevolentAI Office Locations
BenevolentAI has offices in New York and London
London, GB (HQ)
40 Churchway
New York, US
222 Broadway
Report incorrect company information
BenevolentAI Financials and Metrics
Summary Metrics
Founding Date | 2013 |
Total Funding | $215 m |
Latest funding size | $115 m |
Time since last funding | a month ago |
Investors | Lundbeck, Woodford Investment Management, Lansdowne Partners, Upsher Smith Laboratories |
BenevolentAI's latest funding round in April 2018 was reported to be $115 m. In total, BenevolentAI has raised $215 m. BenevolentAI's latest valuation is reported to be $1 b.
BenevolentAI Financials
Market valuation | 1 b |
BenevolentAI Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Proximagen |
Report incorrect company information
BenevolentAI News and Updates
April 19, 2018
Algorithms vs Alzheimers? BenevolentAI Hits $2B High
Some 76 startups now using AI in drug discovery - with traditional discovery then route to market typically taking over a decade
The post Algorithms vs Alzheimers? BenevolentAI Hits $2B High appeared first on Computer Business Review.
April 19, 2018
Woodford-backed BenevolentAI raises $115m as founder allays robot fears
The founder of artificial intelligence (AI) startup BenevolentAI believes robots will be able to exist in a symbiotic relationship with humans, refuting the idea that they will replace all jobs. Speaking to City A.M., Ken Mulvany said AI will "multiply the power of our intellect" in the same way …
April 19, 2018
UPDATE 1-AI drug hunter BenevolentAI worth $2 bln after fund raising
LONDON, April 19 (Reuters) - BenevolentAI, a British drug
developer that uses artificial intelligence to identify new
medicine candidates, said it had raised $115 million in a
funding round that valued it at $2 billion.
April 19, 2018
UK drug discovery startup BenevolentAI raises $115M
U.K.-based artificial intelligence company BenevolentAI Ltd. today announced the completion of a $115 million funding round that values the London startup at a cool $2 billion. The round, said to be one of the largest ever in the AI pharmaceutical sector, was led by BevenolentAI’s existing backers i…
April 18, 2018
BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation
In the ongoing race to build the best and smartest applications that tap into the advances of artificial intelligence, a startup out of London has raised a large round of funding to double down on solving persistent problems in areas like healthcare and energy . BenevolventAI announced today that it…
April 18, 2018
A startup that uses artificial intelligence to discover new drugs just landed a $2 billion valuation
UK-based biotech unicorn BenevolentAI just raised $115 million at a $2 billion valuation.
The company uses artificial intelligence to help discover new drugs to treat conditions like Parkinson's disease and rare cancers.
Applying artificial intelligence to drug discovery — which can often be a l…
Report incorrect company information